13F reference period
Q2 2026
Security Snapshot
SELLAS Life Sciences Group, Inc. - COMMON STOCK (SLS) Institutional Ownership
CUSIP: 81642T209
13F Institutional Holders and Ownership History from Q4 2019 to Q3 2026
Institutions Reporting
192
Shares (Excl. Options)
73,491,015
Price
$14.76
The headline uses the Q2 2026 reference period after its reporting deadline. Available reports may still be incomplete or amended. Newer periods in the history table contain incoming reports and may be incomplete.
Save this security page for your next review
Keep this CUSIP in your watchlists so you can revisit quarter changes from one place. If you create an account from here, we will bring you back after verification.
- Security type / class
- Equity / COMMON STOCK
- Symbol
- SLS on Nasdaq
- All holders as of 30 Jun 2026
- Q2 2026
- Total 13F shares
- 73,491,015
- Total 13F value
- $1,079,069,829
- Portfolio coverage rank
- 0%
- Share change
- +18,620,229
- Value change
- +$308,980,802
- Number of holders
- 192
- Shares outstanding
- 185,665,114
- SEC-reported price per share
- $12.31
- Insider filing price
- $12.31
Latest holder snapshot
5 signals
Issuer context
Names, identifiers, and filing context for this profile.
3 identity fields
13F Shares, Excluding Options vs Price
13F Value, Excluding Options
Total Investors
Filing notes and source
Key facts
- SLS - SELLAS Life Sciences Group, Inc. - COMMON STOCK is tracked under CUSIP 81642T209.
- 192 institutions reported positions in Q2 2026.
- 5 significant owners is listed from Schedule 13D/13G reporting.
Change
- Holder count moved from 160 to 192 between Q1 2026 and Q2 2026.
- SEC-reported value moved from $228,425,549 to $1,079,069,829.
Research use
- You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
- 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.
Evidence
Source: SEC Form 13F
Open SEC evidence
Latest holder context comes from 192 institutions filings for Q2 2026.
Security key
81642T209
13F reference period
Q2 2026
13F holders
192
13D/G owners
5
CIK / CUSIP context first
Open Q2 2026 holders
SLS full holder history
SELLAS Life Sciences Group, Inc. SEC filings
SELLAS Life Sciences Group, Inc. company facts
SELLAS Life Sciences Group, Inc. insider transactions
Broader feeds
Recent Quarterly Holder Reports
Open recent reporting periods for CUSIP 81642T209:
13D/G owners
Significant owners
Large-stake holder rows connected to Schedule 13D/G evidence.
Rows
5
Security
SLS
| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| STATE STREET CORP | 7% | $164,016,562 | 12,996,558 | STATE STREET CORPORATION | 30 Jun 2026 | |||
| BlackRock, Inc. | 6.8% | +28% | $51,336,680 | +$27,281,152 | 12,136,331 | +113% | BlackRock, Inc. | 31 Mar 2026 |
| VANGUARD CAPITAL MANAGEMENT LLC | 5.2% | $121,988,428 | 9,666,278 | Vanguard Capital Management | 30 Jun 2026 | |||
| Anson Funds Management LP | 4.9% | -13% | $31,046,889 | +$6,010,196 | 7,481,178 | +24% | Anson Funds Management LP | 31 Dec 2025 |
| HIGHBRIDGE CAPITAL MANAGEMENT LLC | 3.7% | $24,560,261 | 6,514,658 | Highbridge Capital Management, LLC | 31 Dec 2025 |
As of 30 Jun 2026, 192 institutional investors reported holding 73,491,015 shares of SELLAS Life Sciences Group, Inc. - COMMON STOCK (SLS). This represents 40% of the company’s total 185,665,114 outstanding shares.
13F concentration
Top 25 institutional shareholders
Largest 13F positions for this security by reported shares and value.
Top holder share
35%
| Institution | Ownership % | Shares Held | Share Change % | Portfolio % | Holdings Value |
|---|---|---|---|---|---|
| BlackRock, Inc. | 8.1% | 15,070,302 | +24% | 0% | $222,437,657 |
| STATE STREET CORP | 7% | 12,996,558 | +55% | 0.01% | $191,829,196 |
| VANGUARD CAPITAL MANAGEMENT LLC | 4.4% | 8,226,105 | +9.3% | 0% | $121,417,310 |
| GEODE CAPITAL MANAGEMENT, LLC | 2.6% | 4,884,175 | +25% | 0% | $72,107,010 |
| Anson Funds Management LP | 2.4% | 4,500,000 | 6.2% | $66,420,000 | |
| JONES FINANCIAL COMPANIES LLLP | 1.2% | 2,304,561 | +38% | 0.01% | $28,553,511 |
| VANGUARD PORTFOLIO MANAGEMENT LLC | 1.2% | 2,161,099 | +48% | 0% | $31,897,821 |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | 1.1% | 2,050,597 | +416% | 0.03% | $30,266,812 |
| NORTHERN TRUST CORP | 0.87% | 1,619,928 | +27% | 0% | $23,910,138 |
| VANGUARD FIDUCIARY TRUST CO | 0.72% | 1,335,166 | +11% | 0% | $19,707,050 |
| UBS Group AG | 0.67% | 1,252,757 | +68% | 0% | $18,490,693 |
| MORGAN STANLEY | 0.67% | 1,236,261 | -7.5% | 0% | $18,247,211 |
| DAGCO, INC. | 0.66% | 1,232,433 | +20% | 3.4% | $18,190,706 |
| BNP PARIBAS FINANCIAL MARKETS | 0.58% | 1,072,022 | 0% | 0.01% | $15,823,045 |
| BANK OF AMERICA CORP /DE/ | 0.42% | 787,949 | +23% | 0% | $11,630,128 |
| WELLINGTON MANAGEMENT GROUP LLP | 0.32% | 597,309 | +73% | 0% | $8,816,282 |
| GOLDMAN SACHS GROUP INC | 0.32% | 585,035 | +5.2% | 0% | $8,635,117 |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 0.3% | 565,008 | +18% | 0% | $8,339,518 |
| Bank of New York Mellon Corp | 0.29% | 530,025 | +11% | 0% | $7,823,173 |
| JANE STREET GROUP, LLC | 0.27% | 508,429 | 0% | $7,504,412 | |
| Nuveen, LLC | 0.23% | 418,729 | -38% | 0% | $6,180,440 |
| Opus Capital Group, LLC | 0.21% | 385,604 | +11% | 0.55% | $5,692,000 |
| Invesco Ltd. | 0.2% | 375,342 | -46% | 0% | $5,540,049 |
| Swiss National Bank | 0.19% | 360,400 | 0% | $5,319,504 | |
| XTX Topco Ltd | 0.19% | 359,090 | 0.07% | $5,300,168 |
Quarter history
Institutional holders across reporting periods
Holder count, reported shares/value, and median price by quarter.
Periods
28
Headline period
Q2 2026
Rows shown
1-25 of 28
| Period | 13F Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2026 Q3 | 2,142,559 | $26,373,943 | +$1,156,729 | $12.31 | 27 |
| 2026 Q2 | 73,491,015 | $1,079,069,829 | +$308,980,802 | $14.76 | 192 |
| 2026 Q1 | 53,961,117 | $228,425,549 | +$70,779,572 | $4.23 | 160 |
| 2025 Q4 | 35,512,660 | $133,935,339 | +$23,683,756 | $3.77 | 112 |
| 2025 Q3 | 32,917,301 | $53,012,951 | +$9,796,863 | $1.61 | 92 |
| 2025 Q2 | 26,771,579 | $58,629,839 | +$27,498,028 | $2.19 | 78 |
| 2025 Q1 | 14,287,843 | $15,431,614 | +$8,743,246 | $1.08 | 43 |
| 2024 Q4 | 6,195,241 | $6,443,955 | +$751,049 | $1.04 | 29 |
| 2024 Q3 | 5,385,570 | $6,729,539 | +$1,661,405 | $1.25 | 30 |
| 2024 Q2 | 4,056,846 | $4,828,846 | -$3,466,325 | $1.19 | 29 |
| 2024 Q1 | 7,717,105 | $7,794,727 | +$4,207,509 | $1.01 | 27 |
| 2023 Q4 | 3,493,044 | $3,702,505 | +$352,826 | $1.06 | 29 |
| 2023 Q3 | 2,751,676 | $4,512,830 | -$594,241 | $1.64 | 25 |
| 2023 Q2 | 3,114,137 | $4,889,035 | +$175,383 | $1.57 | 22 |
| 2023 Q1 | 2,996,127 | $4,284,993 | +$1,438,716 | $1.43 | 20 |
| 2022 Q4 | 1,889,269 | $4,456,259 | +$91,291 | $2.36 | 27 |
| 2022 Q3 | 2,186,943 | $4,418,000 | -$1,738,313 | $2.02 | 25 |
| 2022 Q2 | 2,979,307 | $6,641,000 | +$1,671,317 | $2.23 | 23 |
| 2022 Q1 | 1,688,629 | $11,276,000 | -$279,247 | $6.68 | 25 |
| 2021 Q4 | 1,733,782 | $9,586,000 | -$1,340,161 | $5.53 | 26 |
| 2021 Q3 | 1,859,470 | $17,100,000 | -$844,204 | $9.16 | 29 |
| 2021 Q2 | 1,897,926 | $21,282,000 | +$4,739,163 | $11.10 | 28 |
| 2021 Q1 | 1,552,743 | $13,246,990 | +$5,287,808 | $8.54 | 28 |
| 2020 Q4 | 925,075 | $5,374,000 | +$2,503,596 | $5.81 | 17 |
| 2020 Q3 | 616,674 | $1,633,000 | +$397,179 | $2.65 | 10 |